20/20 Biolabs's earnings have been declining at an average annual rate of -50.7%, while the Medical Equipment industry saw earnings growing at 13.6% annually. Revenues have been declining at an average rate of 28.5% per year.
Key information
-50.73%
Earnings growth rate
-49.90%
EPS growth rate
Medical Equipment Industry Growth
8.90%
Revenue growth rate
-28.52%
Return on equity
-186.76%
Net Margin
-276.19%
Last Earnings Update
31 Mar 2026
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How 20/20 Biolabs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
NasdaqCM:AIDX Revenue, expenses and earnings (USD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
2
-5
4
1
31 Dec 25
2
-4
3
1
30 Sep 25
2
-3
3
1
30 Jun 25
2
-4
4
1
31 Mar 25
2
-5
4
1
31 Dec 24
2
-6
5
1
30 Sep 24
2
-6
5
1
30 Jun 24
2
-5
4
1
31 Mar 24
1
-6
4
2
31 Dec 23
1
-6
5
1
30 Sep 23
2
-6
5
1
30 Jun 23
3
-5
5
1
31 Mar 23
7
-2
4
0
31 Dec 22
11
2
3
0
30 Sep 22
14
4
3
0
30 Jun 22
17
6
2
0
31 Mar 22
14
4
2
0
31 Dec 21
10
2
3
0
30 Jun 19
0
-2
2
0
31 Mar 19
0
-2
2
0
31 Dec 18
0
-1
1
0
30 Sep 18
0
-1
1
0
30 Jun 18
0
-1
1
0
31 Mar 18
0
-1
1
0
31 Dec 17
0
-1
1
0
30 Sep 17
0
-1
1
0
30 Jun 17
0
-1
1
0
31 Mar 17
0
-2
2
0
31 Dec 16
0
-2
2
0
31 Dec 15
1
-2
2
1
Quality Earnings: AIDX is currently unprofitable.
Growing Profit Margin: AIDX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AIDX is unprofitable, and losses have increased over the past 5 years at a rate of 50.7% per year.
Accelerating Growth: Unable to compare AIDX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AIDX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.8%).
Return on Equity
High ROE: AIDX has a negative Return on Equity (-186.76%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/02 22:12
End of Day Share Price
2026/06/02 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
20/20 Biolabs, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.